All Stories

  1. Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study

    Article • Neurological Sciences, January 2025, Springer Science + Business Media

    Alberto Doretti

  2. Quantification of serum TDP-43 and neurofilament light chain in patients with amyotrophic lateral sclerosis stratified by UNC13A genotype

    Article • Journal of the Neurological Sciences, November 2024, Elsevier

    Alberto Doretti

  3. Transcranial static magnetic stimulation for amyotrophic lateral sclerosis: a bicentric, randomised, double-blind placebo-controlled phase 2 trial

    Article • The Lancet Regional Health - Europe, October 2024, Elsevier

    Alberto Doretti

  4. QSM-detected iron accumulation in the cerebellar gray matter is selectively associated with executive dysfunction in non-demented ALS patients

    Article • Frontiers in Neurology, September 2024, Frontiers

    Alberto Doretti

  5. Further insights into anti-IgLON5 disease: a case with complex clinical presentation

    Article • BMC Neurology, September 2024, Springer Science + Business Media

    Alberto Doretti

  6. Prevalence and motor-functional correlates of frontotemporal-spectrum disorders in a large cohort of non-demented ALS patients

    Article • Deutsche Zeitschrift für Nervenheilkunde, September 2024, Springer Science + Business Media

    Alberto Doretti

  7. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

    Article • Neurology and Therapy, August 2024, Springer Science + Business Media

    Alberto Doretti

  8. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study

    Article • Brain Sciences, June 2024, MDPI AG

    Alberto Doretti

  9. Ecological validity of performance-based cognitive screeners in amyotrophic lateral sclerosis: preliminary evidence

    Article • Neurological Sciences, June 2024, Springer Science + Business Media

    Alberto Doretti

  10. Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis

    Article • European Journal of Neurology, June 2024, Wiley

    Alberto Doretti

  11. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

    Article • Neurology and Therapy, March 2024, Springer Science + Business Media

    Alberto Doretti

  12. Cervical motion alterations and brain functional connectivity in cervical dystonia

    Article • Parkinsonism & Related Disorders, March 2024, Elsevier

    Alberto Doretti

  13. Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial

    Article • Brain Communications, January 2024, Oxford University Press (OUP)

    Alberto Doretti

  14. Longitudinal Feasibility of the Montreal Cognitive Assessment (MoCA) in Non-Demented ALS Patients

    Article • European Neurology, January 2024, Karger Publishers

    Alberto Doretti

  15. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial

    Article • Trials, December 2023, Springer Science + Business Media

    Alberto Doretti

  16. An exploratory study on counterfactual thinking in amyotrophic lateral sclerosis

    Article • Frontiers in Psychology, December 2023, Frontiers

    Alberto Doretti

  17. The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2023, Springer Science + Business Media

    Alberto Doretti

  18. Frontotemporal-spectrum disorders and functional independence in non-demented ALS patients

    Article • Neurological Sciences, September 2023, Springer Science + Business Media

    Alberto Doretti

  19. The impact of upper motor neuron involvement on clinical features, disease progression and prognosis in amyotrophic lateral sclerosis

    Article • Frontiers in Neurology, September 2023, Frontiers

    Alberto Doretti

  20. Correction: Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson’s disease patients

    Article • Acta Neurovegetativa, September 2023, Springer Science + Business Media

    Alberto Doretti

  21. Bulbar involvement and cognitive features in amyotrophic lateral sclerosis: a retrospective study on 347 patients

    Article • Frontiers in Aging Neuroscience, July 2023, Frontiers

    Alberto Doretti

  22. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis

    Article • Neurological Sciences, June 2023, Springer Science + Business Media

    Alberto Doretti

  23. Single task-level, 2SD-based cutoffs for the Italian version of the Edinburgh Cognitive and Behavioral ALS screen (ECAS)

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, June 2023, Taylor & Francis

    Alberto Doretti

  24. Equating norms between the ALS Cognitive Behavioral Screen (ALS-CBS™) and the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) in non-demented ALS patients

    Article • Deutsche Zeitschrift für Nervenheilkunde, May 2023, Springer Science + Business Media

    Alberto Doretti

  25. Clinical usability of the Story-Based Empathy Task (SET) in non-demented ALS patients

    Article • Neurological Sciences, April 2023, Springer Science + Business Media

    Alberto Doretti

  26. Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson’s disease patients

    Article • Acta Neurovegetativa, March 2023, Springer Science + Business Media

    Alberto Doretti

  27. Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis

    Article • Frontiers in Aging Neuroscience, March 2023, Frontiers

    Alberto Doretti

  28. Correction to: Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, March 2023, Springer Science + Business Media

    Alberto Doretti

  29. Standardization of the Italian ALS-CBS™ Caregiver Behavioral Questionnaire

    Article • Frontiers in Psychology, January 2023, Frontiers

    Alberto Doretti

  30. Relationship between cerebrospinal fluid/serum albumin quotient and phenotype in amyotrophic lateral sclerosis: a retrospective study on 328 patients

    Article • Neurological Sciences, January 2023, Springer Science + Business Media

    Alberto Doretti

  31. Correction to: A video of best practice recommendations for making botulinum toxin therapy safe during the COVID‑19 pandemic

    Article • Neurological Sciences, December 2022, Springer Science + Business Media

    Alberto Doretti

  32. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis

    Article • Annals of Clinical and Translational Neurology, December 2022, Wiley

    Alberto Doretti

  33. Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2022, Springer Science + Business Media

    Alberto Doretti

  34. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

    Article • Frontiers in Neurology, September 2022, Frontiers

    Alberto Doretti

  35. Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy : The multicenter prospective cohort GARLIT...

    Article • European Journal of Neurology, September 2022, Wiley

    Alberto Doretti

  36. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience

    Article • Deutsche Zeitschrift für Nervenheilkunde, June 2022, Springer Science + Business Media

    Alberto Doretti

  37. Ecological Validity of the Montreal Cognitive Assessment in Non-Demented Parkinson’s Disease Patients

    Article • Neurodegenerative Diseases, January 2022, Karger Publishers

    Alberto Doretti

  38. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study

    Article • European Journal of Neurology, December 2021, Wiley

    Alberto Doretti

  39. Validation of the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire for the evaluation of dysphagia in ALS patients

    Article • Neurological Sciences, December 2021, Springer Science + Business Media

    Alberto Doretti

  40. Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study

    Article • Biomolecules, August 2021, MDPI AG

    Alberto Doretti

  41. Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real‐life perspective from the Italian chROnic migraiNe (IRON) project

    Article • Headache The Journal of Head and Face Pain, June 2021, Wiley

    Alberto Doretti

  42. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance

    Article • The Journal of Headache and Pain, May 2021, Springer Science + Business Media

    Dr. Rostyslav V Bubnov, Dr Gentian Vyshka, Professor Anne Ducros, Alberto Doretti

  43. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

    Article • The Journal of Headache and Pain, May 2021, Springer Science + Business Media

    Alberto Doretti

  44. Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis

    Article • Journal of Neurology Neurosurgery & Psychiatry, August 2020, BMJ

    Alberto Doretti

  45. Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis

    Article • NeuroImage Clinical, January 2020, Elsevier

    Alberto Doretti

  46. CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, December 2019, Taylor & Francis

    Alberto Doretti

  47. Headaches in the emergency department –a survey of patients’ characteristics, facts and needs

    Article • The Journal of Headache and Pain, November 2019, Springer Science + Business Media

    Alberto Doretti

  48. PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival

    Article • Neurological Sciences, March 2019, Springer Science + Business Media

    Alberto Doretti

  49. The Complex Interplay Between Depression/Anxiety and Executive Functioning: Insights From the ECAS in a Large ALS Population

    Article • Frontiers in Psychology, April 2018, Frontiers

    Alberto Doretti

  50. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations

    Article • Annals of Neurology, June 2017, Wiley

    Alberto Doretti

  51. Signaling between adipose and nervous tissues are altered in several neurodegenerative diseases

    Article • Journal of Neuroinflammation, April 2017, Springer Science + Business Media

    Lidia Cova, Alberto Doretti

  52. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, May 2016, Taylor & Francis

    Alberto Doretti

  53. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts

    Article • Acta Neuropathologica Communications, May 2016, Springer Science + Business Media

    Alberto Doretti

  54. Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations

    Article • Deutsche Zeitschrift für Nervenheilkunde, July 2012, Springer Science + Business Media

    Alberto Doretti